behavioral disorder

By Targets:	5-HT Receptor (1) Casein Kinase (1) Histone Demethylase (1) LPL Receptor (1) mAChR (1) Melanocortin Receptor (1) Neurotensin Receptor (2)
By Research Areas:	Endocrinology (1) Inflammation/Immunology (1) Neurological Disease (7)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119918

Cycrimine	mAChR	Neurological Disease
Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder .

HY-138830

TAK-418	Histone Demethylase	Neurological Disease
TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC₅₀ of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models .

HY-160236

3-(3-Sulfooxyphenyl)propanoic acid	Others	Neurological Disease
3-(3-Sulfooxyphenyl)propanoic acid (compound M14) is a metabolite of an anti-dementia agent namely echinacoside. 3-(3-Sulfooxyphenyl)propanoic acid has the potential for the research of neurological and behavioral disorders .

HY-18678

Bremelanotide PT-141	Melanocortin Receptor	Endocrinology
Bremelanotide (PT-141) is an analogue of α-melanocyte-stimulating hormone (α-MSH). Bremelanotide activates the mPOA and other hypothalamic and limbic regions of the brain involved in sexual behavior. Bremelanotide can be used for researching hypoactive sexual desire disorders .

HY-107664

SR 142948	Neurotensin Receptor	Neurological Disease
SR 142948 is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC₅₀s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 shows blood-brain permeability and can be used in study of psychiatric disorders .

HY-107664A

SR 142948 dihydrochloride	Neurotensin Receptor	Neurological Disease
SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC₅₀s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC₅₀ of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders .

HY-12443

PF-5006739	Casein Kinase	Neurological Disease
PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC₅₀s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .

HY-163345

5-HT7R antagonist 2

5-HT Receptor

Neurological Disease

5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a K_i of 67 nM, the IC₅₀ values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment .
Pharmacokinetic Analysis ICR Male Mice

药代动力学分析

Plasma	Intravenous Administration	Intraperitoneal Administration
T_max (h)	0.08	0.25
T_1/2 (h)	0.77	1.06
C_max (ng/mL)	33.07	156.44
AUC_last (ng·h/mL)	28.31	143.27
CL (L/h/kg)	41.61	-
V_ss (L/kg)	32.43	-
MRT (h)	0.79	0.93
F (%)	50.60

HY-148115

S1p receptor agonist 2	LPL Receptor	Inflammation/Immunology
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders .

Cat. No.	Product Name

HY-L108

Antidepressant Compound Library	1703 compounds
Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors. Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent. MCE offers a unique collection of 1703 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Antidepressant Compound Library

1703 compounds

Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors.

Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent.

MCE offers a unique collection of 1703 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Cat. No.	Product Name	Target	Research Area

HY-18678

Bremelanotide PT-141	Melanocortin Receptor	Endocrinology
Bremelanotide (PT-141) is an analogue of α-melanocyte-stimulating hormone (α-MSH). Bremelanotide activates the mPOA and other hypothalamic and limbic regions of the brain involved in sexual behavior. Bremelanotide can be used for researching hypoactive sexual desire disorders .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Name
Email *

	Sorry, but the email address you supplied was invalid.